Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study

被引:30
作者
Ge, Li-Ping [1 ,2 ]
Liu, Xi-Yu [1 ,2 ]
Xiao, Yi [1 ,2 ]
Gou, Zong-Chao [1 ,2 ]
Zhao, Shen [1 ,2 ]
Jiang, Yi-Zhou [1 ,2 ]
Di, Gen-Hong [1 ,2 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
occult breast cancer; clinicopathological characteristics; treatment outcomes; SEER database; LYMPH-NODE METASTASIS; UNKNOWN PRIMARY SITE; AXILLARY METASTASES; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; CARCINOMA; MANAGEMENT; LYMPHADENOPATHY; CONSERVATION; SURVIVAL;
D O I
10.2147/CMAR.S169019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Occult breast cancer (OBC) is a rare type of breast cancer that has not been well studied. The clinicopathological characteristics and treatment recommendations for OBC are based on a limited number of retrospective studies and thus remain controversial. Patients and methods: We identified 479 OBC patients and 115,739 non-OBC patients from 2004 to 2014 in and the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological characteristics and survival outcomes were compared between OBC and non-OBC patients. We used the propensity score 1:1 matching analysis to evaluate OBC vs non-OBC comparison using balanced groups with respect to the observed covariates. We further divided the OBC population into four groups based on different treatment strategies. Univariable and multivariable analyses were used to calculate and compare the four treatment outcomes within the OBC population. Results: OBC patients were older, exhibited a more advanced stage, a higher rate of negative estrogen receptor and progesterone receptor status, a higher rate of HER2-positive status, and a higher rate of >= 10 positive lymph nodes, and were less likely to undergo surgical treatment than non-OBC patients. After adjustments for clinicopathological factors, the OBC patients exhibited a significantly better survival than the non-OBC patients (P<0.001). This result was confirmed in a 1:1 matched case -control analysis. Within the four OBC treatment groups, we observed no difference in survival among the mastectomy group, the breast-conserving surgery (BCS) group, and the axillary lymph node dissection (ALND)-only group. The multivariable analysis revealed that the sentinel lymph node dissection-only group had the worst prognosis (P<0.001). Conclusion: OBC has unique clinicopathological characteristics and a favorable prognosis compared with non-OBC. BCS plus ALND and radiotherapy showed a survival benefit that was similar to that of mastectomy for OBC patients.
引用
收藏
页码:4381 / 4391
页数:11
相关论文
共 46 条
[1]   ANALYSIS OF A DIAGNOSTIC STRATEGY FOR PATIENTS WITH SUSPECTED TUMORS OF UNKNOWN ORIGIN [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
LENZI, R ;
HESS, KR ;
RABER, MN .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2094-2103
[2]   Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].
Amir, Eitan ;
Miller, Naomi ;
Geddie, William ;
Freedman, Orit ;
Kassam, Farrah ;
Simmons, Christine ;
Oldfield, Maria ;
Dranitsaris, George ;
Tomlinson, George ;
Laupacis, Andreas ;
Tannock, Ian F. ;
Clemons, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592
[3]   Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-One Matching on the Propensity Score [J].
Austin, Peter C. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 172 (09) :1092-1097
[4]   The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy [J].
Barton, Sarah R. ;
Smith, Ian E. ;
Kirby, Anna M. ;
Ashley, Sue ;
Walsh, Geraldine ;
Parton, Marina .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) :2099-2106
[5]   Association of surgery with improved survival in stage IV breast cancer patients [J].
Blanchard, D. Kay ;
Shetty, Priya B. ;
Hilsenbeck, Susan G. ;
Elledge, Richard M. .
ANNALS OF SURGERY, 2008, 247 (05) :732-738
[6]   Retrospective study of women presenting with axillary metastases from occult breast carcinoma [J].
Blanchard, DK ;
Farley, DR .
WORLD JOURNAL OF SURGERY, 2004, 28 (06) :535-539
[7]   PRESENTATION OF AXILLARY LYMPHADENOPATHY WITHOUT DETECTABLE BREAST PRIMARY (T0 N1B BREAST-CANCER) - EXPERIENCE AT INSTITUT-CURIE [J].
CAMPANA, F ;
FOURQUET, A ;
ASHBY, MA ;
SASTRE, X ;
JULLIEN, D ;
SCHLIENGER, P ;
LABIB, A ;
VILCOQ, JR .
RADIOTHERAPY AND ONCOLOGY, 1989, 15 (04) :321-325
[8]   De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J].
Curigliano, G. ;
Burstein, H. J. ;
Winer, E. P. ;
Gnant, M. ;
Dubsky, P. ;
Loibl, S. ;
Colleoni, M. ;
Regan, M. M. ;
Piccart-Gebhart, M. ;
Senn, H. -J. ;
Thurlimann, B. ;
Andre, F. ;
Baselga, J. ;
Bergh, J. ;
Bonnefoi, H. ;
Brucker, S. Y. ;
Cardoso, F. ;
Carey, L. ;
Ciruelos, E. ;
Cuzick, J. ;
Denkert, C. ;
Di Leo, A. ;
Ejlertsen, B. ;
Francis, P. ;
Galimberti, V. ;
Garber, J. ;
Gulluoglu, B. ;
Goodwin, P. ;
Harbeck, N. ;
Hayes, D. F. ;
Huang, C. -S. ;
Huober, J. ;
Khaled, H. ;
Jassem, J. ;
Jiang, Z. ;
Karlsson, P. ;
Morrow, M. ;
Orecchia, R. ;
Osborne, K. C. ;
Pagani, O. ;
Partridge, A. H. ;
Pritchard, K. ;
Ro, J. ;
Rutgers, E. J. T. ;
Sedlmayer, F. ;
Semiglazov, V. ;
Shao, Z. ;
Smith, I. ;
Toi, M. ;
Tutt, A. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1700-1712
[9]   Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis [J].
Curtit, Elsa ;
Nerich, Virginie ;
Mansi, Laura ;
Chaigneau, Loic ;
Cals, Laurent ;
Villanueva, Cristian ;
Bazan, Fernando ;
Montcuquet, Philippe ;
Meneveau, Nathalie ;
Perrin, Sophie ;
Algros, Marie-Paule ;
Pivot, Xavier .
ONCOLOGIST, 2013, 18 (06) :667-674
[10]  
ELLERBROEK N, 1990, CANCER-AM CANCER SOC, V66, P1461, DOI 10.1002/1097-0142(19901001)66:7<1461::AID-CNCR2820660704>3.0.CO